Ubamatamab

3 trials 2 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

2 Recruiting

0 Completed trials

2 Sponsors

5 Countries

Phase I (FiH)

Phase I (FiH): 3

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Peritoneal cancer index 2 Ovarian cancer recurrent 2 Fallopian tube cancer 2 Endometrial cancer 1

Sponsors using this IMP

Regeneron Pharmaceuticals Inc. 2 Asso De Recherche Cancers Gynecologiques 1

All trials

3 total

REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Res… Pending

2025-524232-20-00 Phase I (FiH) 1 country Asso De Recherche Cancers Gynecologiques
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given with Either Cemiplimab, or Cemiplimab + Fianlimab, … Recruiting

2022-501904-83-00 Phase I (FiH) 3 countries Regeneron Pharmaceuticals Inc.
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination with Cemiplimab in Adult Patients with Recurrent Ovarian Cancer or Other… Recruiting

2024-510783-23-00 Phase I (FiH) 5 countries Regeneron Pharmaceuticals Inc.

Showing 1–3 of 3 trials

← All drugs A–Z